Paridiprubart Biosimilar – Anti-TLR4 mAb – Research Grade

Introduction to Paridiprubart Biosimilar – Anti-TLR4 mAb

Paridiprubart Biosimilar – Anti-TLR4 mAb is a research grade antibody that has been developed to target the Toll-like receptor 4 (TLR4) protein. This protein is a key component of the innate immune system and plays a crucial role in recognizing and responding to microbial infections. The development of this biosimilar antibody has the potential to revolutionize the treatment of various diseases and disorders related to TLR4 dysregulation.

Structure of Paridiprubart Biosimilar – Anti-TLR4 mAb

Paridiprubart Biosimilar – Anti-TLR4 mAb is a monoclonal antibody that specifically binds to the extracellular domain of TLR4. It is composed of two heavy chains and two light chains, with a total molecular weight of approximately 150 kDa. The antibody has a Y-shaped structure, with the antigen-binding sites located at the tips of the arms. This unique structure allows for high specificity and affinity towards TLR4, making it an effective therapeutic agent.

Mechanism of Action of Paridiprubart Biosimilar – Anti-TLR4 mAb

Upon binding to TLR4, Paridiprubart Biosimilar – Anti-TLR4 mAb blocks the activation of downstream signaling pathways involved in the inflammatory response. TLR4 is known to activate the NF-κB and MAPK pathways, leading to the production of pro-inflammatory cytokines and chemokines. By inhibiting this signaling, the antibody helps to reduce the excessive inflammation associated with TLR4 dysregulation.

Title: Applications of Paridiprubart Biosimilar – Anti-TLR4 mAb

Paridiprubart Biosimilar – Anti-TLR4 mAb has a wide range of potential applications in the treatment of various diseases and disorders. It has been shown to be effective in animal models of sepsis, a life-threatening condition caused by an overwhelming immune response to infection. The antibody has also shown promise in treating inflammatory diseases such as rheumatoid arthritis, inflammatory bowel disease, and asthma. Additionally, TLR4 dysregulation has been implicated in the development of certain cancers, and Paridiprubart Biosimilar – Anti-TLR4 mAb may have potential as an anti- cancer therapy.

Advantages of Paridiprubart Biosimilar – Anti-TLR4 mAb

Compared to other TLR4-targeting therapies, Paridiprubart Biosimilar – Anti-TLR4 mAb offers several advantages. As a biosimilar, it has a similar structure and mechanism of action to the original antibody, making it highly specific and effective. It also has a longer half-life, allowing for less frequent dosing and potentially improving patient compliance. Furthermore, as a research grade antibody, it can be used in both in vitro and in vivo studies to further understand the role of TLR4 in various diseases and to develop new treatment strategies.

Conclusion

In summary, Paridiprubart Biosimilar – Anti-TLR4 mAb is a highly specific and effective antibody that targets the TLR4 protein. Its unique structure and mechanism of action make it a promising therapeutic agent for a variety of diseases and disorders. As research in this field continues, this biosimilar antibody has the potential to significantly improve the treatment of TLR4-related conditions.

ProteoGenix catalogue number PX-TA1875. For research use only.

Target: Paridiprubart Biosimilar – Anti-TLR4 mAb – Research Grade; Clonality: Monoclonal Antibody; Expression system: XtenCHO; Buffer: PBS buffer PH7.5; Applications: ELISA, WB.

Available configurations: 50ug, 100ug, 1mg.

Download the manufacturer datasheet